These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 19561532)

  • 1. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.
    Amato RJ; Shingler W; Goonewardena M; de Belin J; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
    J Immunother; 2009 Sep; 32(7):765-72. PubMed ID: 19561532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax).
    Harrop R; Treasure P; de Belin J; Kelleher M; Bolton G; Naylor S; Shingler WH
    Cancer Immunol Immunother; 2012 Dec; 61(12):2283-94. PubMed ID: 22692758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.
    Harrop R; Shingler WH; McDonald M; Treasure P; Amato RJ; Hawkins RE; Kaufman HL; de Belin J; Kelleher M; Goonewardena M; Naylor S
    Cancer Immunol Immunother; 2011 Jun; 60(6):829-37. PubMed ID: 21387109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.
    Harrop R; Chu F; Gabrail N; Srinivas S; Blount D; Ferrari A
    Cancer Immunol Immunother; 2013 Sep; 62(9):1511-20. PubMed ID: 23877659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Scurr M; Pembroke T; Bloom A; Roberts D; Thomson A; Smart K; Bridgeman H; Adams R; Brewster A; Jones R; Gwynne S; Blount D; Harrop R; Wright M; Hills R; Gallimore A; Godkin A
    JAMA Oncol; 2017 Oct; 3(10):e172579. PubMed ID: 28880972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).
    Michael A; Wilson W; Sunshine S; Annels N; Harrop R; Blount D; Pandha H; Lord R; Ngai Y; Nicum S; Stylianou L; Gwyther S; McNeish IA; Hackshaw A; Ledermann J
    Int J Gynecol Cancer; 2024 Aug; 34(8):1225-1231. PubMed ID: 38760075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.
    Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Griffiths R; Steven N; Hawkins RE
    Cancer Immunol Immunother; 2008 Jul; 57(7):977-86. PubMed ID: 18060404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
    Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.
    Tykodi SS; Thompson JA
    Expert Opin Biol Ther; 2008 Dec; 8(12):1947-53. PubMed ID: 18990081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).
    Elkord E; Dangoor A; Burt DJ; Southgate TD; Daayana S; Harrop R; Drijfhout JW; Sherlock D; Hawkins RE; Stern PL
    Cancer Immunol Immunother; 2009 Oct; 58(10):1657-67. PubMed ID: 19221742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated.
    Harrop R; Ryan MG; Myers KA; Redchenko I; Kingsman SM; Carroll MW
    Cancer Immunol Immunother; 2006 Sep; 55(9):1081-90. PubMed ID: 16311730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).
    Meyer RG; Britten CM; Siepmann U; Petzold B; Sagban TA; Lehr HA; Weigle B; Schmitz M; Mateo L; Schmidt B; Bernhard H; Jakob T; Hein R; Schuler G; Schuler-Thurner B; Wagner SN; Drexler I; Sutter G; Arndtz N; Chaplin P; Metz J; Enk A; Huber C; Wölfel T
    Cancer Immunol Immunother; 2005 May; 54(5):453-67. PubMed ID: 15627214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.
    Oudard S; Rixe O; Beuselinck B; Linassier C; Banu E; Machiels JP; Baudard M; Ringeisen F; Velu T; Lefrere-Belda MA; Limacher JM; Fridman WH; Azizi M; Acres B; Tartour E
    Cancer Immunol Immunother; 2011 Feb; 60(2):261-71. PubMed ID: 21069322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.
    Lester JF; Casbard AC; Al-Taei S; Harrop R; Katona L; Attanoos RL; Tabi Z; Griffiths GO
    Oncoimmunology; 2018; 7(12):e1457597. PubMed ID: 30524880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.
    Rudman SM; Jameson MB; McKeage MJ; Savage P; Jodrell DI; Harries M; Acton G; Erlandsson F; Spicer JF
    Clin Cancer Res; 2011 Apr; 17(7):1998-2005. PubMed ID: 21447719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components.
    Waibler Z; Anzaghe M; Frenz T; Schwantes A; Pöhlmann C; Ludwig H; Palomo-Otero M; Alcamí A; Sutter G; Kalinke U
    J Virol; 2009 Feb; 83(4):1563-71. PubMed ID: 19073732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.
    Koster BD; Santegoets SJAM; Harting J; Baars A; van Ham SM; Scheper RJ; Hooijberg E; de Gruijl TD; van den Eertwegh AJM
    Cancer Immunol Immunother; 2019 Jun; 68(6):1025-1035. PubMed ID: 30852622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis.
    Bella Á; Arrizabalaga L; Di Trani CA; Gonzalez-Gomariz J; Gomar C; Russo-Cabrera JS; Olivera I; Cirella A; Fernandez-Sendin M; Alvarez M; Teijeira A; Atay C; Medina-Echeverz J; Hinterberger M; Hochrein H; Melero I; Berraondo P; Aranda F
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37918917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients.
    Suekane S; Nishitani M; Noguchi M; Komohara Y; Kokubu T; Naitoh M; Honma S; Yamada A; Itoh K; Matsuoka K; Kanayama H
    Cancer Sci; 2007 Dec; 98(12):1965-8. PubMed ID: 17919310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.
    Stern PL; Harrop R
    Cancer Immunol Immunother; 2017 Apr; 66(4):415-426. PubMed ID: 27757559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.